Health
COVID-19 Testing Stocks Move Lower After Abbott Receives EUA For 15-Minute Test – Benzinga
Abbott Laboratories (NYSE: ABT) announced late Wednesday the receipt of emergency use authorization from the FDA for its $5, 15-minute COVID-19 antigen …
Abbott Laboratories (NYSE: ABT) announced late Wednesday the receipt of emergency use authorization from the FDA for its $5, 15-minute COVID-19 antigen test.
Abbott’s BinaxNOW could be transformative, Morgan Stanley analyst David Lewis said in a note.
The test is bigger and better than expected, given the $5 price point; the fact that it’s a nasal swab; its better-than-expected performance; and a higher shipment volume, the analyst said.
The Sympathy Move: The announcement, though catalyzing…
-
Noosa News23 hours agoQueensland weather forecast sees sunny weather for last week of winter
-
Business21 hours agoWhy the Betashares Nasdaq 100 ETF could be a perfect buy and hold pick
-
General17 hours agoMigrants raise concerns over Australia’s English tests for visa applicants
-
General23 hours agoEnergy provider ENGIE to ‘correct’ electricity bills for thousands of South Australian customers